1
Home
Companies

Aurinia Pharmaceuticals

#4614

Rank

$2.06B

Marketcap

CA Canada

Country

Aurinia Pharmaceuticals
Leadership team

Mr. Peter S. Greenleaf M.B.A. (Pres, CEO & Director)

Mr. Joseph M. Miller CPA (Chief Financial Officer)

Mr. Matthew Maxwell Donley M.B.A. (Exec. VP of Operations & Strategy)

Products/ Services
Biopharma, Biotechnology, Health Care, Medical, Therapeutics
Number of Employees
100 - 500
Headquarters
Victoria, British Columbia, Canada
Established
2011
Company Registration
SEC CIK number: 0001600620
Revenue
100M - 500M
Traded as
AUPH
Social Media
URL
https://www.auriniapharma.com
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
History

Established in 2012, Aurinia Pharmaceuticals Inc is a biotechnology company in Canada focused on the commercialization of an investigational drug – voclosporin – for the treatment of lupus nephritis. The company is a part of the Healthcare/Biotechnology industry.

Mission
Aurinia Pharmaceuticals is committed to developing and commercializing life-changing therapies to treat rare and serious diseases and to make a real difference in people’s lives.
Vision
To be the trusted leader in developing and delivering innovative and life-changing therapies and services that help people with rare and serious diseases.
Key Team

Mr. Stephen P. Robertson (Exec. VP, Gen. Counsel, Corp. Sec. & Chief Compliance Officer)

Ms. DeDe Sheel (VP of Investor Relation)

Mr. Chris Hays (VP of Marketing)

Mr. Fran Lynch (VP of Sales)

Mr. Michael R. Martin (Chief Bus. Officer)

Ms. Sue Evans (Head of Regulatory Affairs)

Mr. Scott Habig (Chief Commercial Officer)

Recognition and Awards
Aurinia Pharmaceuticals has been the recipient of awards such as “Canrock Partner of the Year” in 2018 and “Top Canadian Biotech” in 2017. In addition, the company has received grants from the Canadian Autoimmune Patient Access Coalition and the Lupus Research Alliance.
References

https://in.investing.com/equities/aurinia-pharmace

https://www.comparably.com/companies/vision/mission

https://www.crunchbase.com/organization/aurinia-pharmaceuticals

https://finance.yahoo.com/quote/AUPH/

https://www.auriniapharma.com

https://sec.report/CIK/0001600620

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Aurinia Pharmaceuticals
Leadership team

Mr. Peter S. Greenleaf M.B.A. (Pres, CEO & Director)

Mr. Joseph M. Miller CPA (Chief Financial Officer)

Mr. Matthew Maxwell Donley M.B.A. (Exec. VP of Operations & Strategy)

Products/ Services
Biopharma, Biotechnology, Health Care, Medical, Therapeutics
Number of Employees
100 - 500
Headquarters
Victoria, British Columbia, Canada
Established
2011
Company Registration
SEC CIK number: 0001600620
Revenue
100M - 500M
Traded as
AUPH
Social Media
URL
https://www.auriniapharma.com